½ÃÀ庸°í¼­
»óǰÄÚµå
1541345

¿µ¾çÀ¯ÀüüÇÐ ½ÃÀå º¸°í¼­ : Á¦Ç° À¯Çü, ¿ëµµ, ÃÖÁ¾»ç¿ëÀÚ, Áö¿ªº°(2024-2032³â)

Nutrigenomics Market Report by Product, Sample Type, Application, End User, and Region 2024-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: IMARC | ÆäÀÌÁö Á¤º¸: ¿µ¹® 141 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¿µ¾çÀ¯ÀüüÇÐ ¼¼°è ½ÃÀå ±Ô¸ð´Â 2023³â 12¾ï 1,260¸¸ ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº 2032³â±îÁö ½ÃÀå ±Ô¸ð°¡ 30¾ï 4,970¸¸ ´Þ·¯¿¡ ´ÞÇØ 2024³âºÎÅÍ 2032³â±îÁö 10.47%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù.

´ºÆ®¸®Á¦³ë¹Í½º¶ó°íµµ ºÒ¸®´Â ¿µ¾çÀ¯ÀüüÇÐÀº ¿µ¾ç, °Ç°­, Àΰ£ À¯ÀüüÀÇ °ü°è¸¦ ºÐ¼®ÇÏ´Â ÀÇÇÐÀÇ ÇÑ ºÐ¾ßÀÔ´Ï´Ù. À¯ÀüÀÚ¿Í ½Ä½À°üÀÇ »ó°ü°ü°è¸¦ ÀÌÇØÇϰí, À¯ÀüÀÚ¿Í ½Ä½À°üÀÌ »ç¶÷ÀÇ °Ç°­°ú ¾Ï, ½ÉÇ÷°üÁúȯ(CVDs), ºñ¸¸°ú °°Àº Áúº´ÀÇ ¹ßº´ À§Çè¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» ÀÌÇØÇÏ´Â µ¥ ÃÊÁ¡À» ¸ÂÃß°í ÀÖ½À´Ï´Ù. ¿µ¾çÀ¯ÀüüÇÐÀº ³ëÈ­¿Í Áúº´¿¡ ´ëÇÑ ¼ÒÀÎÀ» °¨ÁöÇϰí À¯ÀüÀÚÇü¿¡ µû¶ó °³ÀÎÈ­µÈ ½Ä´Ü°ú ¿µ¾ç °èȹÀ» ¼¼¿ì´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¶ÇÇÑ, ÁÖ¿ä ¿µ¾ç¼Ò¿Í ¹Ì·®¿µ¾ç¼ÒÀÇ µ¶¼º ¹× ¾ÈÀü¼º ÇÁ·ÎÆÄÀÏÀ» ÀÌÇØÇÏ°í ½Ä½À°ü °ü·Ã Áúº´À» ¿¹¹æÇÏ´Â µ¥µµ µµ¿òÀÌ µË´Ï´Ù. ÀÌ ¿Ü¿¡µµ ¿µ¾çÀ¯ÀüüÇÐ °Ë»ç´Â ÀϹÝÀûÀ¸·Î Ç÷¾×, º¼ ¹°Æ¼½´, Ÿ¾× µîÀÇ »ùÇÃÀ» äÃëÇÏ¿© °Ë»çÇÏ´Â °ÍÀÌ ÀϹÝÀûÀÔ´Ï´Ù.

¿µ¾çÀ¯ÀüüÇÐ ½ÃÀå µ¿Çâ:

Àü ¼¼°èÀûÀ¸·Î ºñ¸¸ À¯º´·üÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, ½ÃÀå Àü¸ÁÀº ¹à½À´Ï´Ù. ¿µ¾çÀ¯ÀüüÇÐÀº °³ÀÎÀÇ À¯ÀüÀÚ ¼öÁØÀ» ÀÌÇØÇÏ´Â µ¥ µµ¿òÀ̵Ǹç, À̸¦ ¹ÙÅÁÀ¸·Î ÀûÀýÇÑ ¿µ¾ç ½Ä´ÜÀ» Á¦°øÇÔÀ¸·Î½á ºñ¸¸À» ´õ¿í °¨¼Ò½Ãų ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °Ç°­°ú ÇÇÆ®´Ï½º¿¡ ´ëÇÑ ¼ÒºñÀÚÀÇ ¼ºÇâÀÌ Áõ°¡ÇÏ°í Æ¯È÷ ¿îµ¿ ¼±¼ö¿Í ÇÇÆ®´Ï½º ¾ÖÈ£°¡µé »çÀÌ¿¡¼­ °³ÀÎÈ­ µÈ ¿µ¾ç Á¦Ç°¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ½ÃÀå ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. À̿ʹ º°µµ·Î ÁÖ¿ä ±â¾÷µéÀº ¿¬±¸ °³¹ß(R&D) Ȱµ¿¿¡ Àû±ØÀûÀ¸·Î ÅõÀÚÇÏ¿© Àΰ£ À¯ÀüÇÐÀ» ¹ß°ßÀÇ ±âÃÊ·Î »ï¾Æ Çõ½ÅÀûÀÎ ÀÇ·á ¹× ÀáÀçÀû Ä¡·á¹ýÀ» µµÀÔÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¾àÇØÁø ¸é¿ª ü°è¸¦ °­È­Çϰí ÄÝ·¹½ºÅ×·Ñ È­ÇÕ¹° ¼·Ã븦 ÁÙÀÌ´Â µî ƯÁ¤ À¯ÀüÀÚ ÇÁ·ÎÇÊ¿¡ ¸Â´Â ¸ÂÃãÇü ½ÄǰÀ» °³¹ßÇÏ´Â µ¥ ÁÖ·ÂÇϰí ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ºñŸ¹Î D, K, ¿±»ê, öºÐ ºóÇ÷, ÀúÄ®½·Ç÷Áõ, °ñ¿¬È­Áõ, °ÇÇÇÁõ, ±«Ç÷º´, Æä¶ó±×¶ó, ±¸·çº´°ú °°Àº ¿µ¾ç °áÇÌÁõÀÌ Áõ°¡Çϰí ÀÖ´Â °Íµµ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÏ´Â ¿äÀÎÀÔ´Ï´Ù. ÀÌ ¿Ü¿¡µµ ´ëÁßÀÇ °Ç°­ ÀÎ½Ä Áõ°¡, ½ÉÀ庴, ´ç´¢º´ ¹× ±âŸ ¸¸¼º ÁúȯÀÇ À§ÇèÀ» ÁÙÀ̱â À§ÇÑ ¿µ¾ç°¡ ³ôÀº ½Äǰ ¼Òºñ Áõ°¡, ¿µ¾çÀ¯ÀüüÇÐ °Ë»çÀÇ ÀÌÁ¡¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

º» º¸°í¼­¿¡¼­ ´Ù·ç´Â ÁÖ¿ä Áú¹®

  • ¼¼°è ¿µ¾çÀ¯ÀüüÇÐ ½ÃÀåÀº Áö±Ý±îÁö ¾î¶»°Ô ¹ßÀüÇØ¿Ô°í ¾ÕÀ¸·Î ¾î¶»°Ô ¹ßÀüÇÒ °ÍÀΰ¡?
  • COVID-19´Â ¼¼°è ¿µ¾çÀ¯ÀüüÇÐ ½ÃÀå¿¡ ¾î¶² ¿µÇâÀ» ¹ÌÃÆÀ»±î?
  • ÁÖ¿ä Áö¿ª ½ÃÀåÀ̶õ?
  • Á¦Ç°º° ½ÃÀå ÇöȲÀº?
  • »ùÇà À¯Çüº° ½ÃÀå ºÐ¼®Àº?
  • ¿ëµµº° ½ÃÀå ÇöȲÀº?
  • ÃÖÁ¾»ç¿ëÀÚº° ½ÃÀå ºÐ¼®Àº?
  • »ê¾÷ °¡Ä¡»ç½½ÀÇ ´Ù¾çÇÑ ´Ü°è´Â ¹«¾ùÀΰ¡?
  • ¾÷°èÀÇ ÁÖ¿ä ÃËÁø¿äÀΰú °úÁ¦´Â ¹«¾ùÀΰ¡?
  • ¼¼°è ¿µ¾çÀ¯ÀüüÇÐ ½ÃÀåÀÇ ±¸Á¶¿Í ÁÖ¿ä Ç÷¹À̾î´Â?
  • ¾÷°èÀÇ °æÀïÀº ¾î´À Á¤µµÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

  • Á¶»ç ¸ñÀû
  • ÀÌÇØ°ü°èÀÚ
  • µ¥ÀÌÅÍ ¼Ò½º
    • 1Â÷ Á¤º¸
    • 2Â÷ Á¤º¸
  • ½ÃÀå ÃßÁ¤
    • »óÇâ½Ä Á¢±Ù
    • ÇÏÇâ½Ä Á¢±Ù
  • Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼Ò°³

  • °³¿ä
  • ÁÖ¿ä ¾÷°è µ¿Çâ

Á¦5Àå ¼¼°èÀÇ ¿µ¾çÀ¯ÀüüÇÐ ½ÃÀå

  • ½ÃÀå °³¿ä
  • ½ÃÀå ½ÇÀû
  • COVID-19ÀÇ ¿µÇâ
  • ½ÃÀå ¿¹Ãø

Á¦6Àå ½ÃÀå ³»¿ª : Á¦Ç°º°

  • ½Ã¾à°ú ŰƮ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ¼­ºñ½º
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦7Àå ½ÃÀå ³»¿ª : »ùÇà À¯Çüº°

  • Ÿ¾×
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • º¼Á¡¸· ½º¿Ò
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • Ç÷¾×
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ±âŸ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦8Àå ½ÃÀå ³»¿ª : ¿ëµµº°

  • ½ÉÇ÷°üÁúȯ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ºñ¸¸
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ¾Ï ¿¬±¸
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ±âŸ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦9Àå ½ÃÀå ³»¿ª : ÃÖÁ¾»ç¿ëÀÚº°

  • ¿µ¾ç»ç
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ½ºÆ÷Ã÷ Ŭ¸®´Ð
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ±â¾÷¿ë ÇÁ·Î±×·¥
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ±âŸ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦10Àå ½ÃÀå ³»¿ª : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • Çѱ¹
    • È£ÁÖ
    • Àεµ³×½Ã¾Æ
    • ±âŸ
  • À¯·´
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ·¯½Ã¾Æ
    • ±âŸ
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ³»¿ª : ±¹°¡º°
    • ½ÃÀå ¿¹Ãø

Á¦11Àå SWOT ºÐ¼®

  • °³¿ä
  • °­Á¡
  • ¾àÁ¡
  • ±âȸ
  • À§Çù

Á¦12Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦13Àå Porter's Five Forces ºÐ¼®

  • °³¿ä
  • ±¸¸ÅÀÚÀÇ ±³¼··Â
  • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
  • °æÀï Á¤µµ
  • ½Å±Ô Âü¿©¾÷üÀÇ À§Çù
  • ´ëüǰÀÇ À§Çù

Á¦14Àå °¡°Ý ºÐ¼®

Á¦15Àå °æÀï »óȲ

  • ½ÃÀå ±¸Á¶
  • ÁÖ¿ä ±â¾÷
  • ÁÖ¿ä ±â¾÷ °³¿ä
    • BASF SE
    • Cell-Logic
    • Cura Integrative Medicine
    • Danone S.A
    • Fagron
    • Genova Diagnostics
    • Holistic Health International
    • Koninklijke DSM N.V.
    • Metagenics Inc.
    • Nutrigenomix Inc.
    • Xcode Life
ksm 24.09.23

The global nutrigenomics market size reached US$ 1,212.6 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 3,049.7 Million by 2032, exhibiting a growth rate (CAGR) of 10.47% during 2024-2032.

Nutrigenomics, also known as nutritional genomics, is a subset of medical science that analyzes the relationship between nutrition, health, and the human genome. It focuses on understanding the correlation between genes and diet and their effect on a person's health and the risk of developing diseases, such as cancer, cardiovascular diseases (CVDs), and obesity. Nutrigenomics helps detect factors of aging and disease predisposition and create personalized diet or nutrition plans depending on genotype. It also assists in understanding the toxicity and safety profile of macro- and micronutrients and preventing diet-associated diseases. Besides this, nutrigenomics testing is commonly done by taking samples of blood, buccal swabs, and saliva.

Nutrigenomics Market Trends:

The rising prevalence of obesity across the globe is creating a positive outlook for the market. Nutrigenomics helps understand the individual gene level, according to which a proper nutrition diet is given, further resulting in decreased obesity. Additionally, the growing consumer inclination toward health and fitness and the increasing demand for personalized nutrition products, especially among athletes and fitness enthusiasts, is favoring the market growth. Apart from this, key players are extensively investing in research and development (R&D) activities to introduce innovative medicine and potential cures using human genetics as a basis for discovery. They are also focusing on developing tailor-made food to match a particular gene profile, such as strengthening the weak immune system and decreasing the intake of cholesterol compounds, which, in turn, is facilitating the market growth. Moreover, the increasing incidences of nutritional deficiency disorders, such as lack of vitamins D and K, folate, iron anemia, hypocalcemia, osteomalacia, xerophthalmia, scurvy, pellagra, and rickets, are acting as another growth-inducing factor. Besides this, the rising health consciousness among the masses, increasing consumption of nutritious food to mitigate risks of heart diseases, diabetes, and other chronic diseases, and growing awareness about the benefits of nutrigenomic testing are anticipated to drive the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global nutrigenomics market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product, sample type, application and end user.

Breakup by Product:

Reagents and Kits

Services

Breakup by Sample Type:

Saliva

Buccal Swab

Blood

Others

Breakup by Application:

Cardiovascular Diseases

Obesity

Cancer Research

Others

Breakup by End User:

Dieticians

Sport Clinics

Corporate Programs

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being BASF SE, Cell-Logic, Cura Integrative Medicine, Danone S.A, Fagron, Genova Diagnostics, Holistic Health International, Koninklijke DSM N.V., Metagenics Inc., Nutrigenomix Inc. and Xcode Life.

Key Questions Answered in This Report:

  • How has the global nutrigenomics market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global nutrigenomics market?
  • What are the key regional markets?
  • What is the breakup of the market based on the product?
  • What is the breakup of the market based on the sample type?
  • What is the breakup of the market based on the application?
  • What is the breakup of the market based on the end user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global nutrigenomics market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Nutrigenomics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Reagents and Kits
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Services
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Sample Type

  • 7.1 Saliva
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Buccal Swab
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Blood
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Cardiovascular Diseases
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Obesity
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Cancer Research
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Dieticians
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Sport Clinics
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Corporate Programs
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Others
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 BASF SE
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Cell-Logic
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
    • 15.3.3 Cura Integrative Medicine
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
    • 15.3.4 Danone S.A
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
    • 15.3.5 Fagron
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
    • 15.3.6 Genova Diagnostics
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
    • 15.3.7 Holistic Health International
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
    • 15.3.8 Koninklijke DSM N.V.
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
    • 15.3.9 Metagenics Inc.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
    • 15.3.10 Nutrigenomix Inc.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
    • 15.3.11 Xcode Life
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦